Pfizer CEO Made ‘Misleading’ Statements on Vaccinating Children Against COVID-19: UK Watchdog

Pfizer CEO Albert Bourla has made “misleading” and unsubstantiated statements on the merit of giving COVID-19 vaccines to young children, according to a case report published by a UK pharmaceutical watchdog on Jan. 27.

During an interview with the BBC published on Dec. 2, 2021, Bourla was asked whether he believed it was likely that 5- to 11-year-olds in the UK and Europe would be vaccinated against COVID-19 and whether it was a good idea.

The interview was published after the U.S. Food and Drug Administration authorised the use of the Pfizer-BioNTech COVID-19 vaccine for young children, but the UK’s medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), didn’t approve the product for the same age group until Dec. 22, 2021.

While acknowledging that it was up to the UK authorities to decide whether or not to approve and deploy the vaccines, Bourla replied, “I believe it’s a very good idea.”

He cited disruptions in education and the potential of developing so-called long-COVID, saying, “so there is no doubt in my mind about the benefits completely are in favour of doing it.”

Syringes in front of displayed Biontech and Pfizer logos on Nov. 10, 2020. (Dado Ruvic/Illustration/Reuters)

Following complaints from UsForThem—a children’s welfare campaign group founded in response to the COVID-19 lockdowns—a panel from the Prescription Medicines Code of Practice Authority (PMCPA) ruled that Bourla’s statements breached a number of rules in the Association of the British Pharmaceutical Industry (ABPI) code of practice.

After Pfizer appealed against the ruling, an appeal board upheld five counts of breaches of three ABPI codes that require information and claims to be accurate, balanced, capable of substantiation, not raising unfounded hopes of successful treatment, and not be misleading with respect to the safety of the product.

The PMCPA described Bourla’s statements as being of a “strong unqualified nature.” It also said they inferred there was “no need to be concerned about potential side-effects of vaccination in healthy children aged 5-11” and that the implication was “misleading and incapable of substantiation.”

The PMCPA said it has received an undertaking from Pfizer to prevent similar breaches in the future.

Code breakers are charged for administrative costs, but the self-regulatory body does not have the power to impose fines or other legal sanctions.

Bourla was initially found to have also breached the code for promoting the Pfizer-BioNTech vaccine in the 5–11 age group when it was not authorised by the MHRA, but the appeal board overturned the ruling, agreeing with Pfizer that its CEO was asked a specific question and it was not unreasonable to talk about the issue in principle. The board also noted that two other COVID-19 vaccines were also under investigation for the age group.

The appeal board also overturned previous rulings that said Pfizer had failed to maintain high standards and brought discredit upon the industry.

Most Serious Rulings

Pfizer didn’t respond to The Epoch Times’ request for comment. In a previous statement to The Telegraph in November 2022, when the newspaper obtained the unpublished ruling, a spokesman for Pfizer said the company was “committed to the highest levels of integrity in any interaction with the public.”

“We are pleased the UK’s PMCPA Appeal Board found Pfizer to have maintained high standards and upheld confidence in our industry, the two most serious rulings in this complaint from a UK campaign group,” the statement reads.

“In the UK, we have always endeavoured to follow the principles and letter of our industry Code of Practice throughout. We will review the case report in detail when we receive it, to inform future activity,” it added.

Speaking to The Epoch Times on Tuesday, Ben Kingsley, head of legal affairs at UsForThem, said he was “thrilled” the regulator ultimately agreed with them that the Pfizer CEO’s statements were misleading and unsubstantiated after the pharmaceutical giant opposed their claims “with all of the resources at its disposal” throughout the process.

Commenting on Pfizer’s previous statement on the ruling, Kingsley said the group “found it quite surprising” that Pfizer would consider the rulings about maintaining high standards and upholding confidence in the industry the “most serious” of all.

“I think to the average member of the public, we’d regard misleading us about the safety of their product to be plenty more serious than bringing the repute of the pharmaceutical industry down,” he said.

“So I think it tells you something about the mindset and the priorities of pharma executives that they regard the abuse of the industry as being a more serious matter than misleading the public.”

(L-R) Professor Wei Shen Lim, chair of JCVI’s COVID-19 subcommittee; Professor Jonathan Van Tam, deputy chief medical officer for England; and Dr. June Raine, chief executive of the Medicines and Healthcare products Regulatory Agency, attend a media briefing at Downing Street Briefing Room in London on Nov. 29, 2021. (Stefan Rousseau/WPA Pool/Getty Images)

n June 2021, the UK government’s advisory body on vaccines, the Joint Committee on Vaccination and Immunisation (JCVI), declined to recommend COVID-19 vaccines for healthy children aged between 12 and 15, given the “marginal” benefits young teens would get from the vaccines and the lack of long-term data on the side-effects, including myocarditis.

But the vaccines were later offered to the age group after UK chief medical officers made a recommendation based on wider considerations, including the disruption to children’s education—attributed by some to COVID-19 and by others to the political decision to make children who test positive stay out of school.

The JCVI later recommended a one-off “non-urgent offer” to vaccinate 5- to 11-year-olds. The offer ended in August last year.

In is most recent recommendation, the JCVI said under–50s who are at lower risk of getting seriously ill with COVID-19 will soon be unable to get a booster shot. The offer of primary doses will also end for low-risk people in all age groups.

Resource of Article: Pfizer CEO Made ‘Misleading’ Statements on Vaccinating Children Against COVID-19: UK Watchdog

Link: https://link.theepochtimes.com/mkt_app/uk-watchdog-rules-pfizer-ceo-made-misleading-statements-on-vaccinating-children-against-covid-19_5022549.html

Pfizer Signs Agreement to Provide the European Union with PAXLOVID™

  • SearchHamburgerPfizer Signs Agreement to Provide the European Union with PAXLOVID™Wednesday, November 23, 2022 – 11:00amShare

    New agreement to supply up to 3.4 million treatment courses to countries across Europe; this deal supplements the courses provided to 17 EU member states under existing bilateral agreementsDeliveries to participating countries commencing imminently NEW YORK, November 23, 2022Pfizer Inc. (NYSE: PFE) today announced an agreement with the European Commission (EC) to supply its COVID-19 oral therapy, PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) to countries participating in the Joint Procurement Agreement across Europe. This agreement, negotiated with the Health Emergency Preparedness and Response Authority (HERA) of the EC, is in addition to the bilateral agreements Pfizer has previously signed with 17 EU Member States. This agreement will supply participating countries up to 3.4 million treatment courses upon orders being placed. Under the terms of the agreement, Pfizer will begin delivery of the initial treatment quantities ordered by the participating countries in November, in parallel to deliveries underway as part of existing bilateral agreements.“Clinical data and real-world evidence for PAXLOVID have shown that it can be an important tool in helping to reduce hospitalizations and deaths in those at increased risk of serious illness from COVID-19,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “As the region prepares for winter and a possible resurgence in COVID-19 infections, the accessibility and availability of treatment options is of the utmost importance. We are pleased to be working with the European Commission to make PAXLOVID available to more patients across Europe.”PAXLOVID is currently authorized for conditional or emergency use in more than 70 countries across the globe. Following the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize PAXLOVID, a conditional marketing authorization (CMA) for PAXLOVID was granted in January 2022 for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe. Europe plays a critical role in the delivery of PAXLOVID to patients across the globe, as the site of four of Pfizer’s key PAXLOVID manufacturing facilities.About PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets)
    PAXLOVID is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV-2 3CL protease inhibitor) therapy. It was developed to be administered orally so that it can be prescribed early after infection, potentially helping patients avoid severe illness (which can lead to hospitalization and death). Nirmatrelvir [PF-07321332], which originated in Pfizer laboratories, is designed to block the activity of the Mpro, an enzyme that the coronavirus needs to replicate. Co-administration with a low dose of ritonavir helps slow the metabolism, or breakdown, of nirmatrelvir in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus.Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. PAXLOVID, however, works intracellularly by binding to the highly conserved Mpro (3CL protease) of the SARS-CoV-2 virus to inhibit viral replication. Nirmatrelvir has shown consistent in vitro antiviral activity against the following variants: Alpha, Beta, Delta, Gamma, Lambda, Mu, and Omicron BA.1, BA.2 and BA.4.PAXLOVID is generally administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice-daily for five days. One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course.Our Commitment to Access
    Pfizer is committed to working toward equitable access to our oral COVID-19 treatment, PAXLOVID, for high-risk patients in need, aiming to deliver safe and effective oral treatment as soon as possible and at an affordable price. If authorized or approved, during the pandemic, Pfizer will offer its oral therapy through a tiered pricing approach based on the income level of each country to promote equity of access across the globe; high and upper-middle income countries will pay more than lower-income countries. Pfizer has established a comprehensive strategy in close partnership with worldwide governments, international global health leaders, including WHO’s Access to COVID-19 Tools Accelerator (ACT-A), and global manufacturers to optimize supply and access of PAXLOVID all around the world. This includes:

    • Multilateral Supply Agreements: Agreements in place with UNICEFfor the supply of up to 4 million treatment courses to 137 low- and middle-income countries and with Global Fund for up to 6 million treatment courses for supply to 132 Global-Fund grant-eligible countries, subject to regulatory approval or authorization.Expanding Access to Patent-Protected Medicines in Lower-Income Countries: Launched An Accord for a Healthier World, a first-of-its-kind initiative to enable sustained, equitable access to high-quality medicines and vaccines for 1.2 billion people living in lower-income countries. Pfizer has committed to provide its patent-protected medicines and vaccines available in the U.S. or European Union, including PAXLOVID, on a not-for-profit basis to 45 lower-income countries around the world and will collaborate with government and global health leaders to address barriers that limit access beyond supply, like diagnosis, education, infrastructure, storage and more.Accelerating Testing and Treatment: Joined the COVID Treatment Quick Start Consortium, a joint initiative implemented by Duke University, the Clinton Health Access Initiative (CHAI), COVID Collaborative and Americares with support from Pfizer, Open Society Foundations and the Conrad Hilton Foundation. Pfizer will provide treatment courses of PAXLOVID, as well as financial support, to support the Consortium’s efforts to accelerate COVID-19 testing and improve access to treatments in under-resourced parts of the world. The consortium has launched test and treat initiatives in partnership with ten countries in Africa and Southeast Asia. Humanitarian Treatment Donation: As part of its humanitarian response, Pfizer donated 200K treatment courses of PAXLOVID to Ukraine.Voluntary Licensing: Signed a voluntary license agreement with Medicines Patent Pool (MPP) to enable the development and distribution of generic versions of Pfizer’s oral treatment to further expand long-term global supply and access. MPP has signed sublicense agreements with 38 manufacturers, who will supply the generic versions in 95 low- and lower-middle-income countries.

    U.S. FDA Emergency Use Authorization Statement
    PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death.
    The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.AUTHORIZED USE
    The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PAXLOVID for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.LIMITATIONS OF AUTHORIZED USE

    • PAXLOVID is not authorized for initiation of treatment in patients requiring hospitalization due to severe or critical COVID-19PAXLOVID is not authorized for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19PAXLOVID is not authorized for use for longer than 5 consecutive days

    PAXLOVID may be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs.

    PAXLOVID may also be prescribed for an individual patient by a state-licensed pharmacist under the following conditions:

    • Sufficient information is available, such as through access to health records less than 12 months old or consultation with a health care provider in an established provider‑patient relationship with the individual patient, to assess renal and hepatic function; and Sufficient information is available, such as through access to health records, patient reporting of medical history, or consultation with a health care provider in an established provider‑patient relationship with the individual patient, to obtain a comprehensive list of medications (prescribed and non-prescribed) that the patient is taking to assess for potential drug interaction.

    The state-licensed pharmacist should refer an individual patient for clinical evaluation (e.g., telehealth, in-person visit) with a physician, advanced practice registered nurse, or physician assistant licensed or authorized under state law to prescribe drugs, if any of the following apply:

    • Sufficient information is not available to assess renal and hepatic function.Sufficient information is not available to assess for a potential drug interaction.Modification of other medications is needed due to a potential drug interaction.PAXLOVID is not an appropriate therapeutic option based on the authorized Fact Sheet for Healthcare Providers or due to potential drug interactions for which recommended monitoring would not be feasible.

    PAXLOVID is not approved for any use, including for use for the treatment of COVID-19.

    PAXLOVID is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PAXLOVID under 564(b)(1) of the Food Drug and Cosmetic Act unless the authorization is terminated or revoked sooner.IMPORTANT SAFETY INFORMATION
    PAXLOVID is contraindicated in patients with a history of clinically significant hypersensitivity reactions (eg, toxic epidermal necrolysis [TEN] or Stevens-Johnson syndrome) to its active ingredients (nirmatrelvir or ritonavir) or any other components of the product.
    Drugs listed in this section are a guide and not considered a comprehensive list of all drugs that may be contraindicated with PAXLOVID. The healthcare provider should consult other appropriate resources such as the prescribing information for the interacting drug for comprehensive information on dosing or monitoring with concomitant use of a strong CYP3A inhibitor such as ritonavir.
    PAXLOVID is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions:

    • Alpha1-adrenoreceptor antagonist: alfuzosinAntianginal: ranolazineAntiarrhythmic: amiodarone, dronedarone, flecainide, propafenone, quinidineAnti-gout: colchicineAntipsychotics: lurasidone, pimozideBenign prostatic hyperplasia agents: silodosinCardiovascular agents: eplerenone, ivabradineErgot derivatives: dihydroergotamine, ergotamine, methylergonovineHMG-CoA reductase inhibitors: lovastatin, simvastatinImmunosuppressants: voclosporinMicrosomal triglyceride transfer protein inhibitor: lomitapideMigraine medications: eletriptan, ubrogepantMineralocorticoid receptor antagonists: finerenoneOpioid antagonists: naloxegolPDE5 inhibitor: sildenafil (Revatio®) when used for pulmonary arterial hypertensionSedative/hypnotics: triazolam, oral midazolamSerotonin receptor 1A agonist/serotonin receptor 2A antagonist: flibanserinVasopressin receptor antagonists: tolvaptan

    PAXLOVID is contraindicated with drugs that are potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. PAXLOVID cannot be started immediately after discontinuation of any of the following medications due to the delayed offset of the recently discontinued CYP3A inducer:

    • Anticancer drugs: apalutamideAnticonvulsant: carbamazepine, phenobarbital, primidone, phenytoin Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftorAntimycobacterials: rifampinHerbal Products: St. John’s Wort (hypericum perforatum)

    There are limited clinical data available for PAXLOVID. Serious and unexpected adverse events may occur that have not been previously reported with PAXLOVID use.
    Risk of Serious Adverse Reactions Due to Drug Interactions: Initiation of PAXLOVID, a CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving PAXLOVID, may increase plasma concentrations of medications metabolized by CYP3A. Initiation of medications that inhibit or induce CYP3A may increase or decrease concentrations of PAXLOVID, respectively. These interactions may lead to:

    • Clinically significant adverse reactions, potentially leading to severe, life-threatening, or fatal events from greater exposures of concomitant medicationsClinically significant adverse reactions from greater exposures of PAXLOVIDLoss of therapeutic effect of PAXLOVID and possible development of viral resistance

    Consult Table 1 of the Fact Sheet for Healthcare Providers for clinically significant drug interactions, including contraindicated drugs. Drugs listed in Table 1 are a guide and not considered a comprehensive list of all possible drugs that may interact with PAXLOVID. Consider the potential for drug interactions prior to and during PAXLOVID therapy; review concomitant medications during PAXLOVID therapy and monitor for the adverse reactions associated with the concomitant medications.Anaphylaxis and other hypersensitivity reactions have been reported with PAXLOVID. Cases of Toxic Epidermal Necrolysis and Stevens-Johnson syndrome have been reported with ritonavir, a component of PAXLOVID (refer to NORVIR prescribing information). If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue PAXLOVID and initiate appropriate medications and/or supportive care.Hepatotoxicity: Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir. Therefore, caution should be exercised when administering PAXLOVID to patients with pre-existing liver diseases, liver enzyme abnormalities, or hepatitis.
    Because nirmatrelvir is co-administered with ritonavir, there may be a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection.Adverse events in the PAXLOVID group (≥1%) that occurred at a greater frequency (≥5 subject difference) than in the placebo group were dysgeusia (6% and

Pfizer and Clear Creek collaborate on SARS-CoV-2 PLpro inhibitors for COVID-19

Pfizer and Clear Creek collaborate on SARS-CoV-2 PLpro inhibitors for COVID-19

Microscope and coronavirus illustration
Microscope and coronavirus illustration

Dec. 7, 2022

Pfizer Inc. and Clear Creek Bio Inc. have entered into a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the SARS-CoV-2 papain-like protease (PLpro) for the oral treatment of COVID-19. PLpro is an essential enzyme, which, along with the main protease (Mpro), plays an important role in viral replication. Under the agreement, the two companies will work together to identify a PLpro candidate to progress into the clinic, at which time Pfizer will be solely responsible for further development and commercialization activities. Clear Creek Bio will receive an undisclosed upfront payment and will be eligible to receive additional potential milestone payments plus royalties on future product sales (Pfizer News Release).

Source: https://www.bioworld.com/articles/692088-pfizer-and-clear-creek-collaborate-on-sars-cov-2-plpro-inhibitors-for-covid-19

COVID-19 HUMANITY BETRAYAL MEMORY PROJECT: Document Your Story

Crimes Against Humanity

We are witnessing crimes against humanity taking place all across this country and all over the world. Our friends and family members have been and are being harmed by measures ostensibly implemented to protect them and keep them safe.
We are witnessing crimes against humanity taking place all across this country and all over the world. Our friends and family members have been and are being harmed by measures ostensibly implemented to protect them and keep them safe.

Document Your Story

Document Your Story
Click Here to Document Your Story

Please fill out as much information as you can. While most fields are optional and the entire form does not to be completed in order to submit your story, the more information you are able to provide, the better we will be able to serve you and advance our mission.

Click link to document your story in the COVID-19 HUMANITY BETRAYAL MEMORY PROJECT.

Document Your Story Here

Source: https://chbmp.org/document/

DOCUMENTED CASES

Crimes Against Humanity
View All Cases Now
Click Here to View All Cases Now

Click link below to view documented cases in the COVID-19 HUMANITY BETRAYAL MEMORY PROJECT.

View Documented Cases

Crimes Against Humanity

We are witnessing crimes against humanity taking place all across this country and all over the world. Our friends and family members have been and are being harmed by measures ostensibly implemented to protect them and keep them safe.

Two Years of Isolation, Abuse & Mistreatment

For over two years, the people have been abused, manipulated, maligned, and sometimes even murdered in the name of public health. This has been and is still going on in hospitals, assisted living facilities, juvenile detention centers, schools, and really anywhere else that institutional mandates can be applied with force. We, the people harmed by these unamerican and unconstitutional measures, are dedicated to pushing back on this encroachment on our civil liberties, and putting a stop to these grievous harms the people are being forced to endure at the hands of those entrusted to protect them.

Never Forget

This is one of many projects developed to defend our liberties undertaken by the FFFF. The primary goal of this project is to document, archive, and assist those impacted by these crimes against humanity. We are taking testimonials from those who have survived the protocols mandated by these disastrous policies, interviewing victims and family members to validate their stories, and documenting and archiving everything. We will not allow the victims of these crimes against humanity to go unheard.

Managed By FFFF Citizens Task Force 

The FFFF Task Force is composed of survivors, victims, and families of victims who have suffered grievous harm as a result of malicious public health policy. If you have been harmed by the disastrous public health policies of the last two years and would like to help others and raise awareness, please Join the FFFF Task Force today.

Source: https://chbmp.org/document/

REPORT: 33-Year-Old Mother Paralyzed Following COVID Jab

REPORT: 33-Year-Old Mother Paralyzed Following COVID Jab

Another day, another tragedy. It’s become an all-too-familiar story by now.

Her doctor, her government and the mainstream media – all assured her it would be OK, and that the new experimental mRNA synthetic pharmaceutical cocktail was ‘safe and effective.’ In a mere moment, her entire life turned on a dime.

Just 12 hours after receiving her experimental COVID-19 gene therapy injection manufactured by Pfizer, 33-year-old mother Rachel Cecere’s body began rebelling against her, and she was later diagnosed with “acute distress to the nervous system.” Rachel found herself paralyzed from the neck down, but three weeks later she was able to regain strength in her upper body, except for her left hand.

The timing of the onset of her disease just after receiving the experimental ‘vaccine’ is suspect to say the least. Was her disability brought on by the jab? If so, who will be held accountable?

She is not alone either. To date the various vaccine adverse reactions databases in the US, UK, and EU alone contain, on the aggregate, millions of reported injuries, as well as tens of thousands of deaths following the experimental shot.

She asks in desperation, “When is this going to get better?” Watch: 

This video was published at Odysee on February 2, 2022

READ MORE VACCINE NEWS AT: 21st Century Wire Vaccine Files

PLEASE HELP SUPPORT OUR INDEPENDENT MEDIA PLATFORM HERE

ALSO JOIN OUR TELEGRAM CHANNEL

Situation Update: Chernobyl Underground Tunnels! Russian Soldiers Rescue Children Chained in Tunnels and They Connect to Tunnels Under Biden Property! Parasites in Pfizer Vax Hatching Eggs! – We The People News | Opinion – Conservative | Before It’s News

Although it pains me so, we have the right to know. How the captured children, tragically suffered so. We may not know the real truth, or do we already know. How the dark ones did prey, on our children so. She means the FBI engaged in sabotage and false flag
— Read on beforeitsnews.com/opinion-conservative/2022/03/situation-update-chernobyl-underground-tunnels-russian-soldiers-rescue-children-chained-in-tunnels-they-connect-to-tunnels-under-biden-property-parasites-in-pfizer-vax-hatching-eggs-we-the-3621727.html

Kakistocracy: noun, government by the worst persons; a form of government in which the worst persons are in power

Kakistocracy: noun, government by the worst persons; a form of government in which the worst persons are in power.

The old saying goes that even a blind squirrel finds a nut occasionally.  So you might think that during a 50-year political career, the odds would dictate that Joe Biden would, once in a blue moon, make a correct decision — just based on the odds.  But you’d be mistaken.  Biden has stumbled and bumbled from one disastrous decision to the next.  Disastrous, that is, for America.  Biden himself has prospered handsomely in spite of his glaring incompetence and corruption. 

Biden’s long Senate career was based on being the credit card companies’ man in Washington.  While crowing endlessly about the working class being “his people,” Biden sponsored bills allowing bank issuers to charge egregious interest rates and to make it harder for working men to escape the credit trap through bankruptcy.

When Biden chaired the Senate Judiciary Committee, he turned the confirmation of Clarence Thomas into a political smear campaign that descended into a degenerate three-ring circus. In his first campaign for president, he failed to garner a single percentage point before having to withdraw when confronted with his past lies and blatant plagiarism. He literally stole a speech detailing a British politician’s life story. He ran again in 2008 but again failed to reach even one percent of the vote.

When Barack Obama took him off the primary trash heap to make him vice president, Biden first made a hash out of the 2009 American Recovery and Reinvestment Act, wasting hundreds of billions on boondoggles and giveaways to Democrat cronies. Little of the recovery billions was spent on anything useful to America. Biden went on to manage our relations with China and Ukraine, pocketing untold millions for himself and his family by selling out America’s security interests.

By the time he ran for president again in 2020 he was a spent husk of his former corrupt and incompetent self, delivering asinine performances in the Iowa caucus and New Hampshire primary. When the Democrat establishment propped him up to once again stop Bernie Sanders, Biden was set up for the strangest presidential campaign in modern history. While Donald Trump barnstormed the nation with packed, enthusiastic rallies, Biden cowered in his basement, occasionally venturing out to speak with a few dozen voters sitting in circles drawn on the floor.

For his vice presidential pick, he chose — if you can believe it — an even more buffoonish candidate than himself.

Had it not been for Mark Zuckerberg buying and staffing government election offices in swing states, and the media and Big Tech’s censorship of the Biden family’s corruption, Biden would now be enjoying his dotage in Delaware, creeping on unsuspecting children with yarns of Corn Pop and South African arrests.

Instead, the man with one of the most astonishing records of abject failure in Washington was installed in the White House, and he has remained true to form.  As one of a hundred senators and then as vice president, there was a limit to how much damage he could do.  But as president, the shackles have been removed.

His first agenda item was to throttle our oil and gas sector, offshoring tens of thousands of good paying jobs to Russia and the Middle East — along with our energy independence. He threw open our southern border and encouraged virtually unlimited illegal immigration — during a global pandemic.

He sponsored trillions of dollars in wasteful spending, pushing our national debt to over $31 trillion.  Were it not for two Democrat senators who had not yet taken leave of their senses, it would have been even worse.  As it is, Biden has sparked the largest one-year increase in inflation in 40 years.

Biden’s “defund the police” rhetoric delivered us soaring violent crime in Democrat-run cities, while he sicced federal law enforcement on parents who object too strenuously to their children being indoctrinated with anti-White racism and LGBTQIA+ ideology. 

It can truly be said that as president, Biden’s record of failure remains unblemished.  

But now comes what may be the capstone on Biden’s long history of buffoonery and corruption.  In Ukraine, we have an armed conflict that threatens to plunge the world into an economic depression and raises the specter of nuclear war.  Not only did Biden set the stage for this calamity when, as vice president, he was in charge of Ukraine policy and led Kiev to believe that NATO membership was in Ukraine’s future, but on the eve of the Russian invasion, he refused to admit that it was not.  Then Biden all but admitted to Vladimir Putin — on live TV, no less — that NATO would not defend Ukraine if Russia chose to invade. 

In the aftermath of Russia’s invasion, Biden and his administration have crafted sanctions that seem almost designed to boomerang on America’s and Europe’s fragile post-pandemic economies, while forcing Russia into a deeper alliance with China

With the U.S. over $31 trillion in debt, Biden seems totally oblivious to the perilous position of the U.S. dollar as the world’s reserve currency and the consequences should that privileged position end. 

Economists predict that food and gasoline will cost the average U.S. household an additional $3,000 this year, and inflation threatens to push millions of lower-middle income-earners into abject poverty.

And bumbling, corrupt Joe Biden isn’t yet halfway through his first — and please God, last — term.

Image: Gage Skidmore via Flickr, CC BY-SA 2.0.
Image: Gage Skidmore via Flickr, CC BY-SA 2.0.

Image: Gage Skidmore via Flickr, CC BY-SA 2.0.

Jim Daws is a recovering talk radio host at jimdaws.com.